In Brief: Endovascular Technologies, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Endovascular Technologies, Inc.: Expects to begin prospective Phase II clinical trials of its Aortoiliac EGS system, which is designed to treat aneurysms in which one iliac artery is unsuitable for endovascular attachment of an implant. The planned 20-site study, for which an investigational device exemption application recently was approved by FDA, will compare mortality, complications, and length of hospital stay among patients treated with the Aortoiliac EGS and those receiving conventional treatment...